Boston Scientific in the news

Boston Scientific is reorganizing its business units into three segments and appointing a new Chief Operating Officer.

Boston Scientific is reorganizing its operating structure into three segments and appointing a new COO and finance leadership to align with its expanding portfolio.

Boston Scientific named Joseph M. Fitzgerald as COO and restructured into three segments for efficiency and growth.

Boston Scientific named Joseph M. Fitzgerald as COO and restructured into three new segments to streamline operations and support growth.

Stryker is a better stock to buy than Boston Scientific due to its superior free cash flow generation, despite Boston Scientific's better margins and lower valuation multiples.

Boston Scientific's stock is experiencing volatility due to cautious analyst ratings, a recent cyberattack, and weakness in key product areas, despite a history of revenue growth.

Citigroup reduced its price target for Boston Scientific to $48 from $50 while keeping a Neutral rating.

A Singapore court refused Boston Scientific's bid to prevent a former director from working for rival Johnson & Johnson.

Bernstein SocGen Group lowered Boston Scientific's price target to $54 due to concerns about Abbott's Amulet 360 taking market share from Boston Scientific's Watchman.

Boston Scientific promotes incontinence treatment options with a call to action to learn more.

RBC Capital and J.P. Morgan maintained Buy ratings on Boston Scientific with price targets of $70 and $56, respectively, following strong Q2 earnings and positive insider sentiment.

Boston Scientific's stock declined due to a cybersecurity incident impacting its financial guidance, despite strong Q2 results and ongoing analyst support.

Bernstein lowered Boston Scientific's price target to $54 from $60, while retaining an 'Outperform' rating.

Boston Scientific stock has delivered significant compounded returns over the past 15 years, with a $1000 investment growing to over $7500.

Boston Scientific is recalling its spinal cord stimulator systems due to an issue that may cause them to fail to deliver intended therapy, potentially leading to increased pain for patients.

Boston Scientific's stock fell, and the company is preparing for its Q3 2026 earnings report, with analysts forecasting growth in earnings and revenue.

Elutia received an $8 million payment from Boston Scientific, securing funding until 2029 for its NXT-41x commercial launch.

Boston Scientific's stock reached a 52-week low due to a significant year-long decline and a recent cyberattack, though recovery efforts are underway and some analysts suggest it may be undervalued.

Elutia secured an $8 million payment from Boston Scientific, extending its funding through 2029.

Elutia received an $8 million payment from Boston Scientific, concluding a divestiture and extending Elutia's funding into 2029.